4-Phenylbutyric Acid Treatment Reduces Low-Molecular-Weight Proteinuria in a Clcn5 Knock-in Mouse Model for Dent Disease-1
International Journal of Molecular Sciences · 25.07.2024 · 25 (15) · 8110
DOI: 10.3390/ijms25158110 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.07.2024. Verfasst von Ana Perdomo-Ramírez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigacion, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigacion Sanitaria de Canarias (IISC), 38010 Santa Cr…. Hauptthemen laut MEDLINE: Chloride Channels, Disease Models, Animal, Proteinuria, Gene Knock-In Techniques. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Asociacion de la Enfermedad de Dent (ASDENT), Universidad de La Laguna.
Abstract (Originalsprache)
Dent disease-1 (DD-1) is a rare X-linked tubular disorder characterized by low-molecular-weight proteinuria (LMWP), hypercalciuria, nephrolithiasis and nephrocalcinosis. This disease is caused by inactivating mutations in the CLCN5 gene which encodes the voltage-gated ClC-5 chloride/proton antiporter. Currently, the treatment of DD-1 is only supportive and focused on delaying the progression of the disease. Here, we generated and characterized a Clcn5 knock-in mouse model that carries a pathogenic CLCN5 variant, c. 1566_1568delTGT; p.Val523del, which has been previously detected in several DD-1 unrelated patients, and presents the main clinical manifestations of DD-1 such as high levels of urinary b2-microglobulin, phosphate and calcium. Mutation p.Val523del causes partial ClC-5 retention in the endoplasmic reticulum. Additionally, we assessed the ability of sodium 4-phenylbutyrate, a small chemical chaperone, to ameliorate DD-1 symptoms in this mouse model. The proposed model would be of significant value in the investigation of the fundamental pathological processes underlying DD-1 and in the development of effective therapeutic strategies for this rare condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unidad de Investigacion, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigacion Sanitaria de Canarias (IISC), 38010 Santa Cruz de Tenerife, Spain.
- Seccion Medicina, Departamento de Medicina Fisica y Farmacologia, Facultad de Ciencias de la Salud, Universidad de La Laguna, 38200 Santa Cruz de Tenerife, Spain.
- Unidad de Nefrologia Pediatrica, Hospital Universitario Nuestra Señora de Candelaria, 38010 Santa Cruz de Tenerife, Spain.
ORCID-Profile: Ana Perdomo-Ramírez, Félix Claverie-Martin
Förderung
- Instituto de Salud Carlos III
- Asociacion de la Enfermedad de Dent (ASDENT)
- Universidad de La Laguna
Zitieren
APA
Perdomo-Ramírez, A., Ramos-Trujillo, E., Machado, J. D., García-Nieto, V., Mura-Escorche, G., Claverie-Martin, F., & RenalTube Group (2024). 4-Phenylbutyric Acid Treatment Reduces Low-Molecular-Weight Proteinuria in a Clcn5 Knock-in Mouse Model for Dent Disease-1. International Journal of Molecular Sciences, 25(15), 8110. https://doi.org/10.3390/ijms25158110
Vancouver
Perdomo-Ramírez A, Ramos-Trujillo E, Machado JD, García-Nieto V, Mura-Escorche G, Claverie-Martin F, et al. 4-Phenylbutyric Acid Treatment Reduces Low-Molecular-Weight Proteinuria in a Clcn5 Knock-in Mouse Model for Dent Disease-1. International Journal of Molecular Sciences. 2024;25(15):8110. doi:10.3390/ijms25158110
BibTeX
@article{PerdomoRamrez2024,
author = {Perdomo-Ramírez, Ana and Ramos-Trujillo, Elena and Machado, Jose David and García-Nieto, Victor and Mura-Escorche, Glorián and Claverie-Martin, Félix and RenalTube Group, RenalTube Group},
title = {4-Phenylbutyric Acid Treatment Reduces Low-Molecular-Weight Proteinuria in a Clcn5 Knock-in Mouse Model for Dent Disease-1},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {15},
pages = {8110},
doi = {10.3390/ijms25158110}
}
EUVIMED